| Symbol | BCAB |
|---|---|
| Name | BIOATLA, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 11085 TORREYANA ROAD, SAN DIEGO, California, 92121, United States |
| Telephone | +1 858 558-0708 |
| Fax | — |
| — | |
| Website | https://www.bioatla.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001826892 |
| Description | BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise Mecbotamab vedotin, Ozuriftabmab vedotin, BA3071, and Bispecific antibody programs. Additional info from NASDAQ: |
Vasquez Christian 🔴 sold 257 shares of BioAtla, Inc. (BCAB) at $3.93 Transaction Date: Mar 11, 2026 | Filing ID: 259699
Read moreSievers Eric 🔴 sold 494 shares of BioAtla, Inc. (BCAB) at $3.93 Transaction Date: Mar 11, 2026 | Filing ID: 259689
Read moreSHORT JAY M PHD 🔴 sold 898 shares of BioAtla, Inc. (BCAB) at $3.93 Transaction Date: Mar 12, 2026 | Filing ID: 259702
Read moreNew Form ARS - BioAtla, Inc. <b>Filed:</b> 2026-06-03 <b>AccNo:</b> 0001193125-26-255438 <b>Size:</b> 12 MB
Read moreNew Form DEFA14A - BioAtla, Inc. <b>Filed:</b> 2026-06-03 <b>AccNo:</b> 0001193125-26-255434 <b>Size:</b> 2 MB
Read moreNew Form DEF 14A - BioAtla, Inc. <b>Filed:</b> 2026-06-03 <b>AccNo:</b> 0001193125-26-255422 <b>Size:</b> 6 MB
Read moreBioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Read moreNew Form S-8 - BioAtla, Inc. <b>Filed:</b> 2026-03-31 <b>AccNo:</b> 0001193125-26-134492 <b>Size:</b> 847 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05808634 | Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma. | Phase1 | Advanced Adenocarcinoma | Recruiting | 2023-07-14 | 2028-09-15 | ClinicalTrials.gov |
| NCT05271604 | A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic S… | Phase2 | Head and Neck Cancer | Completed | 2022-12-13 | 2025-09-22 | ClinicalTrials.gov |
| NCT05180799 | A Phase 1/2 Study of BA3071 in Patients With Solid Tumors | Phase1 | NSCLC | Active_Not_Recruiting | 2022-08-03 | 2026-06-30 | ClinicalTrials.gov |
| NCT04681131 | CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC | Phase2 | Non-Small-Cell Lung Cancer | Completed | 2021-03-17 | 2025-07-09 | ClinicalTrials.gov |
| NCT03853343 | Seaweed Extract Supplementation and Metabolic Biomarkers | Na | Metabolic Syndrome | Completed | 2018-06-28 | 2022-01-30 | ClinicalTrials.gov |
| NCT03504488 | CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Can… | Phase1 | Non Small Cell Lung Cancer | Completed | 2018-06-27 | 2024-12-30 | ClinicalTrials.gov |
| NCT03425279 | CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sar… | Phase1 | Undifferentiated Pleomorphic Sarcoma | Completed | 2018-02-15 | 2025-01-08 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Toripalimab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT04918186 |
| ENB003 | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT04918186 |
| BA3021 | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT04918186 |
| BA3011 | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT04918186 |
| Durvalumab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT04918186 |
| Placebo | Other | Approved | Metabolic Syndrome | COMPLETED | NCT03853343 |
| Seaweed extract | Other | Approved | Metabolic Syndrome | COMPLETED | NCT03853343 |
| Placebo | Other | Approved | Metabolic Syndrome | COMPLETED | NCT03853343 |
| Seaweed extract | Other | Approved | Metabolic Syndrome | COMPLETED | NCT03853343 |
| PD-1 inhibitor | Other | Phase PHASE1 | Non Small Cell Lung Cancer | COMPLETED | NCT03504488 |
| CAB-ROR2-ADC | Other | Phase PHASE1 | Non Small Cell Lung Cancer | COMPLETED | NCT03504488 |
| Pemetrexed (Alimta) | Other | Phase PHASE1 | NSCLC | ACTIVE_NOT_RECRUITING | NCT05180799 |
| Pembrolizumab | Other | Phase PHASE1 | NSCLC | ACTIVE_NOT_RECRUITING | NCT05180799 |
| Nivolumab | Other | Phase PHASE1 | NSCLC | ACTIVE_NOT_RECRUITING | NCT05180799 |
| BA3071 | Other | Phase PHASE1 | NSCLC | ACTIVE_NOT_RECRUITING | NCT05180799 |
| PD-1 inhibitor | Other | Phase PHASE1 | Undifferentiated Pleomorphic Sarcoma | COMPLETED | NCT03425279 |
| CAB-AXL-ADC | Other | Phase PHASE1 | Undifferentiated Pleomorphic Sarcoma | COMPLETED | NCT03425279 |
| BA3182 | Other | Phase PHASE1 | Advanced Adenocarcinoma | RECRUITING | NCT05808634 |
| PD-1 inhibitor | Other | Phase PHASE2 | Non-Small-Cell Lung Cancer | COMPLETED | NCT04681131 |
| CAB-AXL-ADC | Other | Phase PHASE2 | Non-Small-Cell Lung Cancer | COMPLETED | NCT04681131 |
| Cetuximab | Other | Phase PHASE2 | Head and Neck Cancer | COMPLETED | NCT05271604 |
| Evalstotug (BA3071) | Other | Phase PHASE2 | Head and Neck Cancer | COMPLETED | NCT05271604 |
| Pembrolizumab | Other | Phase PHASE2 | Head and Neck Cancer | COMPLETED | NCT05271604 |
| Ozuriftamab Vedotin | Other | Phase PHASE2 | Head and Neck Cancer | COMPLETED | NCT05271604 |
| Toripalimab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT04918186 |
| ENB003 | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT04918186 |
| BA3021 | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT04918186 |
| BA3011 | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT04918186 |
| Durvalumab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT04918186 |
| BA3182 | DRUG | Phase PHASE1 | Advanced Adenocarcinoma | RECRUITING | NCT05808634 |
| Cetuximab | BIOLOGICAL | Phase PHASE2 | Head and Neck Cancer | COMPLETED | NCT05271604 |
| Evalstotug (BA3071) | BIOLOGICAL | Phase PHASE2 | Head and Neck Cancer | COMPLETED | NCT05271604 |
| Ozuriftamab Vedotin | BIOLOGICAL | Phase PHASE2 | Head and Neck Cancer | COMPLETED | NCT05271604 |
| Pemetrexed (Alimta) | DRUG | Phase PHASE1 | NSCLC | ACTIVE_NOT_RECRUITING | NCT05180799 |
| Pembrolizumab | BIOLOGICAL | Phase PHASE2 | Head and Neck Cancer | COMPLETED | NCT05271604 |
| Nivolumab | BIOLOGICAL | Phase PHASE1 | NSCLC | ACTIVE_NOT_RECRUITING | NCT05180799 |
| BA3071 | BIOLOGICAL | Phase PHASE1 | NSCLC | ACTIVE_NOT_RECRUITING | NCT05180799 |
| Toripalimab | DRUG | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT04918186 |
| ENB003 | DRUG | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT04918186 |
| BA3021 | DRUG | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT04918186 |
| BA3011 | DRUG | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT04918186 |
| Durvalumab | DRUG | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT04918186 |
| CAB-ROR2-ADC | BIOLOGICAL | Phase PHASE1 | Non Small Cell Lung Cancer | COMPLETED | NCT03504488 |
| PD-1 inhibitor | BIOLOGICAL | Phase PHASE2 | Non-Small-Cell Lung Cancer | COMPLETED | NCT04681131 |
| CAB-AXL-ADC | BIOLOGICAL | Phase PHASE2 | Non-Small-Cell Lung Cancer | COMPLETED | NCT04681131 |